Companies, institutions and individuals are invited to submit data on their products that are in the preclinical pipeline that fulfil the below inclusion criteria. Data submitted should be non-confidential and will be made available publicly on the WHO Global Health R&D Observatory.
Identifying potential antibiotic leads is painfully slow, but these researchers identified 5 in only 6 years
ENABLE surpassed their goal of identifying 3 leads for new antibiotics. With several more compounds in the pipeline, the project has been extended.
On 28 and 29 January, the Access to Medicine Foundation will host an investor webinar about the newly published 2020 AMR Benchmark. It will provide investors with an introduction about the materiality of AMR for the pharmaceutical industry and present the results from the most recent independent comparison of how 30 different pharmaceutical companies are responding to rising rates of drug-resistant infections.
The 2nd AMR Benchmark report will go live on Tuesday 21 January. It will give a reality check on how the biggest players in anti-infectives markets are responding to drug resistance and access challenges. After launch, the research will first be presented in a dedicated session at the 2020 WEF Annual Meeting in Davos.
Declining private investment and lack of innovation in the development of new antibiotics are undermining efforts to combat drug-resistant infections, says the World Health Organization (WHO).
In early October, the World Bank Group released a report on antimicrobial resistance. By looking at several country-based case studies, along with the growing literature on AMR, this report outlines factors both helping and burdening interventions towards controlling AMR, especially in low- and middle-income countries (LMICs).